Next Generation Cancer Care Symposium
Intercontinental Dallas Hotel
October 20, 2007
Program Description and Learning Objectives
Recent advances in bio-technology, and the better understanding of tumor biology, genomics and proteomics have revolutionized the field of oncology and the future of cancer care. This has led the oncology community to focus on the concept of personalized medicine in providing less toxic and more effective therapies to individual patients and their cancers. Hand in hand arises the need to address the increasing needs of cancer survivors and quality of life issues as fortunately our patients live longer and longer. The development of algorithms and technology to facilitate risk assessment in the approach of cancer care from this perspective continues to evolve and will facilitate better understanding of prognostic information and therapeutic choices for individual patients. Blending a patient’s quest for cure with the potential risks benefits of widely used complementary and alternative therapies will also need to be better understood. At the end of this activity, attendees will be able to explain the future direction of the dynamic field of oncology, the necessity to practice individualized medicine. They will learn how tumor biology influences better understanding of prognosis as well as therapeutic planning to optimize patient outcomes. The issues of survivorship for cancer patients as well as review of the understanding of the field of complementary and alternative therapies as it pertains to the care of oncology patients will be addressed.
Target Audience
This activity is intended for oncologists, internists, specialists, advanced practitioners, nurses, and other healthcare professionals interested in the future direction of oncology.
Educational Objectives
After participating in this educational activity, participants should be able to:
1. Apply algorithms and technology to facilitate risk assessment for recurrence in individual patients.
2. Assess the implications of genomics and proteomics in better understanding tumor biology and prognostic assessments.
3. Summarize advances in proteomics and genomics and their implications for the treatment of colon and breast and lung cancers.
4. Discuss how improving cancer survivorship has made concrete planning a necessity for patients for their long-term cancer risks, preventative medicine, follow-up care and health maintenance with a focus on quality of life.
5. Define how to measure quality cancer care and how to develop strategies for improving health outcomes.
6. Discuss the role of integrative and complementary medicine in the future of cancer care.
Method of Participation
Lectures, visual aids, presentations, and discussions will be utilized to engage attendees and enhance the learning process.
Accreditation Statement:
Physicians:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Texas Medical Association and NexGen Oncology. The Texas Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Nurses:
Nursing contact hours have been applied for through the Texas Nurses Association, an accredited approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
Designation Statement:
The TMA designates this educational activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Hours:
|
